Mia Helfrich1, Peter Dorschner1, Kathryn Thomas1,2, Valentina Stosor3,2, Michael G Ison1,3,2. 1. Northwestern University Transplant Outcomes Research Collaborative, Chicago, IL, USA. 2. Division of Organ Transplantation, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. 3. Division of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Abstract
BACKGROUND: Most epidemiologic studies of opportunistic infections (OI) following abdominal organ transplantation are derived prior to the era of contemporary immunosuppression and prophylaxis. These studies suggest that most OI occur within the first 6 months post transplant. METHOD: In this single-center, retrospective cohort study, we describe the epidemiology of OI in 359 consecutive abdominal organ transplant recipients, in the era of contemporary prophylaxis practices and alemtuzumab induction in kidney and simultaneous pancreas-kidney transplant recipients. RESULTS: Ninety patients (25.1%) developed OI, with 53.3% of these occurring beyond 6 months. The most common OI were BK polyomavirus nephropathy (5.0%), cytomegalovirus (10.2%), varicella zoster virus (4.4%), and herpes simplex virus (1.1%), which typically occurred after discontinuation of antiviral prophylaxis, and Clostridium difficile infections (7.8%). CONCLUSION: OI had no impact on patient or graft survival at 12 months post transplant. In the era of contemporary immunosuppression and prophylaxis, a significant proportion of OI occur beyond 6 months. Additional strategies may be important to reduce the incidence of such late-onset infections.
BACKGROUND: Most epidemiologic studies of opportunistic infections (OI) following abdominal organ transplantation are derived prior to the era of contemporary immunosuppression and prophylaxis. These studies suggest that most OI occur within the first 6 months post transplant. METHOD: In this single-center, retrospective cohort study, we describe the epidemiology of OI in 359 consecutive abdominal organ transplant recipients, in the era of contemporary prophylaxis practices and alemtuzumab induction in kidney and simultaneous pancreas-kidney transplant recipients. RESULTS: Ninety patients (25.1%) developed OI, with 53.3% of these occurring beyond 6 months. The most common OI were BK polyomavirus nephropathy (5.0%), cytomegalovirus (10.2%), varicella zoster virus (4.4%), and herpes simplex virus (1.1%), which typically occurred after discontinuation of antiviral prophylaxis, and Clostridium difficile infections (7.8%). CONCLUSION: OI had no impact on patient or graft survival at 12 months post transplant. In the era of contemporary immunosuppression and prophylaxis, a significant proportion of OI occur beyond 6 months. Additional strategies may be important to reduce the incidence of such late-onset infections.
Authors: Emma E Ilett; Marie Helleberg; Joanne Reekie; Daniel D Murray; Signe M Wulff; Mark P Khurana; Amanda Mocroft; Gedske Daugaard; Michael Perch; Allan Rasmussen; Søren S Sørensen; Finn Gustafsson; Niels Frimodt-Møller; Henrik Sengeløv; Jens Lundgren Journal: Open Forum Infect Dis Date: 2019-02-19 Impact factor: 3.835
Authors: Anne-Grete Märtson; Martijn Bakker; Hans Blokzijl; Erik A M Verschuuren; Stefan P Berger; Lambert F R Span; Tjip S van der Werf; Jan-Willem C Alffenaar Journal: BMJ Open Date: 2020-01-07 Impact factor: 2.692
Authors: Christian van Delden; Susanne Stampf; Hans H Hirsch; Oriol Manuel; Pascal Meylan; Alexia Cusini; Cédric Hirzel; Nina Khanna; Maja Weisser; Christian Garzoni; Katja Boggian; Christoph Berger; David Nadal; Michael Koller; Ramon Saccilotto; Nicolas J Mueller Journal: Clin Infect Dis Date: 2020-10-23 Impact factor: 9.079
Authors: You Luo; Zuofu Tang; Xiao Hu; Shuo Lu; Bin Miao; Songlin Hong; Haiyun Bai; Chen Sun; Jiang Qiu; Huiying Liang; Ning Na Journal: Ann Transl Med Date: 2020-02
Authors: Philippe Attias; Giovanna Melica; David Boutboul; Nathalie De Castro; Vincent Audard; Thomas Stehlé; Géraldine Gaube; Slim Fourati; Françoise Botterel; Vincent Fihman; Etienne Audureau; Philippe Grimbert; Marie Matignon Journal: J Clin Med Date: 2019-04-30 Impact factor: 4.241